{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:40:29Z","timestamp":1783042829648,"version":"3.54.6"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016619","name":"MyoKardia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.amepre.2022.03.027","type":"journal-article","created":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T23:35:23Z","timestamp":1653262523000},"page":"440-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Fixed-Dose Combination (Polypill) for Cardiovascular Disease Prevention: A Meta-Analysis"],"prefix":"10.1016","volume":"63","author":[{"given":"Abdelrahman I.","family":"Abushouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0150-8917","authenticated-orcid":false,"given":"Ahmed","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-9212","authenticated-orcid":false,"given":"Omar","family":"Abdelfattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-5084","authenticated-orcid":false,"given":"Erin D.","family":"Michos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amgad","family":"Mentias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-6464","authenticated-orcid":false,"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7404","key":"10.1016\/j.amepre.2022.03.027_bib0001","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","article-title":"A strategy to reduce cardiovascular disease by more than 80% [published correction appears in BMJ. 2003;327(7415):586] [published correction appears in BMJ. 2006;60(9):823]","volume":"326","author":"Wald","year":"2003","journal-title":"BMJ"},{"issue":"20","key":"10.1016\/j.amepre.2022.03.027_bib0002","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1161\/CIRCULATIONAHA.109.873232","article-title":"The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions","volume":"122","author":"Lonn","year":"2010","journal-title":"Circulation"},{"issue":"10073","key":"10.1016\/j.amepre.2022.03.027_bib0003","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0140-6736(17)30553-6","article-title":"Uses of polypills for cardiovascular disease and evidence to date","volume":"389","author":"Huffman","year":"2017","journal-title":"Lancet"},{"issue":"10199","key":"10.1016\/j.amepre.2022.03.027_bib0004","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0140-6736(19)31791-X","article-title":"Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial","volume":"394","author":"Roshandel","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.amepre.2022.03.027_bib0005","doi-asserted-by":"crossref","first-page":"g3318","DOI":"10.1136\/bmj.g3318","article-title":"Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care","volume":"348","author":"Selak","year":"2014","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.amepre.2022.03.027_bib0006","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2013.277064","article-title":"Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial [published correction appears in JAMA. 2013;310(14):1507]","volume":"310","author":"Thom","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2022.03.027_bib0007","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.amepre.2022.03.027_bib0008","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"10.1016\/j.amepre.2022.03.027_bib0009","first-page":"e19857","article-title":"An international randomised placebo-controlled trial of a four-component combination pill (\u201cpolypill\u201d) in people with raised cardiovascular risk [published correction appears in PLoS One. 2019;14(11):e0225924]","volume":"6","author":"Collaborative Group","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.amepre.2022.03.027_bib0010","doi-asserted-by":"crossref","first-page":"e41297","DOI":"10.1371\/journal.pone.0041297","article-title":"Randomized polypill crossover trial in people aged 50 and over","volume":"7","author":"Wald","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.amepre.2022.03.027_bib0011","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/2047487314530382","article-title":"A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk","volume":"22","author":"Patel","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.amepre.2022.03.027_bib0012","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.2147\/DDDT.S112873","volume":"10","author":"Park","year":"2016","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"10.1016\/j.amepre.2022.03.027_bib0013","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without aspirin in persons without cardiovascular disease","volume":"384","author":"Yusuf","year":"2021","journal-title":"N Engl J Med"},{"issue":"9672","key":"10.1016\/j.amepre.2022.03.027_bib0014","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(09)60611-5","article-title":"Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial","volume":"373","author":"Yusuf","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.amepre.2022.03.027_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-6215-12-3","article-title":"A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization","volume":"12","author":"Soliman","year":"2011","journal-title":"Trials"},{"issue":"12","key":"10.1016\/j.amepre.2022.03.027_bib0016","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1815359","article-title":"Polypill for cardiovascular disease prevention in an underserved population","volume":"381","author":"Mu\u00f1oz","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amepre.2022.03.027_bib0017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1751-7176.2008.00058.x","article-title":"The use of a single-pill calcium channel blocker\/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study","volume":"11","author":"Neutel","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.amepre.2022.03.027_bib0018","doi-asserted-by":"crossref","unstructured":"Grimm R, Malik M, Yunis C, Sutradhar S, Kursun A, TOGETHER Investigators. Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine\/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. Vasc Health Risk Manag. 2010;6(1):261\u2012271. https:\/\/doi.org\/10.2147\/vhrm.s7710.","DOI":"10.2147\/VHRM.S7710"},{"issue":"9","key":"10.1016\/j.amepre.2022.03.027_bib0019","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1742-1241.2010.02412.x","article-title":"A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (\u2018polypill\u2019) on cardiovascular risk factors","volume":"64","author":"Malekzadeh","year":"2010","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.amepre.2022.03.027_bib0020","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1185\/03007995.2011.555754","article-title":"Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial","volume":"27","author":"Zamorano","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"10.1016\/j.amepre.2022.03.027_bib0021","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1185\/03007995.2012.725391","article-title":"Changes in calculated coronary heart disease risk using proactive multifactorial intervention versus continued usual care in Latin-American and non-Latin-American patients enrolled in the CRUCIAL trial","volume":"28","author":"Pavia","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.amepre.2022.03.027_bib0022","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.3346\/jkms.2013.28.12.1741","article-title":"Proactive multifactorial intervention strategy reduces the risk of cardiovascular disease estimated with region-specific risk assessment models in Pacific Asian patients participating in the CRUCIAL Trial","volume":"28","author":"Cho","year":"2013","journal-title":"J Korean Med Sci"},{"issue":"6","key":"10.1016\/j.amepre.2022.03.027_bib0023","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1185\/03007995.2013.783795","article-title":"Post hoc analysis of the cluster randomized usual care versus caduet investigation assessing long-term risk (CRUCIAL) trial","volume":"29","author":"Hradec","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.amepre.2022.03.027_bib0024","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1185\/03007995.2013.781503","article-title":"Reduction in cardiovascular risk using proactive multifactorial intervention versus usual care in younger (< 65 years) and older (\u2265 65 years) patients in the CRUCIAL trial","volume":"29","author":"Kim","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amepre.2022.03.027_bib0025","doi-asserted-by":"crossref","unstructured":"Cho EJ, Kim JH, Sutradhar S, Yunis C, Westergaard M, CRUCIAL trial investigators. Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis. Vasc Health Risk Manag. 2014;10:145\u2013156. https:\/\/doi.org\/10.2147\/VHRM.S54586.","DOI":"10.2147\/VHRM.S54586"},{"issue":"12","key":"10.1016\/j.amepre.2022.03.027_bib0026","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1177\/2047487315624523","article-title":"Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease","volume":"23","author":"Lafeber","year":"2016","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"10.1016\/j.amepre.2022.03.027_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-002313","article-title":"INterpreting the Processes of the UMPIRE Trial (INPUT): protocol for a qualitative process evaluation study of a fixed-dose combination (FDC) strategy to improve adherence to cardiovascular medications","volume":"3","author":"Salam","year":"2013","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.amepre.2022.03.027_bib0028","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/2047487312463278","article-title":"Use of a multidrug pill in reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe","volume":"21","author":"Thom","year":"2014","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"10.1016\/j.amepre.2022.03.027_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008018","article-title":"Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease","volume":"5","author":"Wood","year":"2015","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.amepre.2022.03.027_bib0030","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.cct.2011.07.006","article-title":"IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care","volume":"32","author":"Selak","year":"2011","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.amepre.2022.03.027_bib0031","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.hlc.2014.04.159","article-title":"Polypills for high risk patients: results of a New Zealand randomised controlled trial","volume":"23","author":"Selak","year":"2014","journal-title":"Hear Lung Circ"},{"issue":"14","key":"10.1016\/j.amepre.2022.03.027_bib0032","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1177\/2047487316637196","article-title":"Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications: findings from a pragmatic randomised controlled trial","volume":"23","author":"Selak","year":"2016","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.amepre.2022.03.027_bib0033","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/1471-2458-10-458","article-title":"Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk","volume":"10","author":"Liu","year":"2010","journal-title":"BMC Public Health"},{"issue":"11","key":"10.1016\/j.amepre.2022.03.027_bib0034","doi-asserted-by":"crossref","first-page":"671","DOI":"10.5694\/mja14.00266","article-title":"An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial","volume":"201","author":"Laba","year":"2014","journal-title":"Med J Aust"},{"issue":"5","key":"10.1016\/j.amepre.2022.03.027_bib0035","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1177\/1060028015570468","article-title":"Patient preferences for a polypill for the prevention of cardiovascular diseases","volume":"49","author":"Laba","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.amepre.2022.03.027_bib0036","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5694\/mja14.00581","article-title":"Facilitators and barriers to implementation of a pragmatic clinical trial in Aboriginal health services","volume":"203","author":"Liu","year":"2015","journal-title":"Med J Aust"},{"issue":"3","key":"10.1016\/j.amepre.2022.03.027_bib0037","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/CIRCOUTCOMES.115.001483","article-title":"Patients\u2019 and providers\u2019 perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial","volume":"8","author":"Liu","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"10.1016\/j.amepre.2022.03.027_bib0038","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/1755-5922.12151","article-title":"The effect of a cardiovascular polypill strategy on pill burden","volume":"33","author":"Truelove","year":"2015","journal-title":"Cardiovasc Ther"},{"issue":"12","key":"10.1016\/j.amepre.2022.03.027_bib0039","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1177\/2047487314550803","article-title":"Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial","volume":"22","author":"Ostovaneh","year":"2015","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"10.1016\/j.amepre.2022.03.027_bib0040","first-page":"551","article-title":"Reliability analysis of a newly developed questionnaire for quality control of follow-up visits in PolyIran study","volume":"19","author":"Roshandel","year":"2016","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.amepre.2022.03.027_bib0041","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ahj.2018.07.012","article-title":"The International Polycap Study-3 (TIPS-3): design, baseline characteristics and challenges in conduct","volume":"206","author":"Joseph","year":"2018","journal-title":"Am Heart J"},{"issue":"21","key":"10.1016\/j.amepre.2022.03.027_bib0042","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amepre.2022.03.027_bib0043","article-title":"Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases","volume":"3","author":"Bahiru","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"10306","key":"10.1016\/j.amepre.2022.03.027_bib0044","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(21)01827-4","article-title":"Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis","volume":"398","author":"Joseph","year":"2021","journal-title":"Lancet"},{"issue":"7557","key":"10.1016\/j.amepre.2022.03.027_bib0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.38875.675486.55","article-title":"A meta-analysis of the association between adherence to drug therapy and mortality","volume":"333","author":"Simpson","year":"2006","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.amepre.2022.03.027_bib0046","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/CIRCULATIONAHA.108.768986","article-title":"Medication adherence: its importance in cardiovascular outcomes","volume":"119","author":"Ho","year":"2009","journal-title":"Circulation"},{"issue":"10073","key":"10.1016\/j.amepre.2022.03.027_bib0047","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(17)30558-5","article-title":"Putting polypills into practice: challenges and lessons learned","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"issue":"9678","key":"10.1016\/j.amepre.2022.03.027_bib0048","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"issue":"10152","key":"10.1016\/j.amepre.2022.03.027_bib0049","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.amepre.2022.03.027_bib0050","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.amepre.2022.03.027_bib0051","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.amepre.2022.03.027_bib0052","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/heartjnl-2018-313108","article-title":"Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials","volume":"105","author":"Selak","year":"2019","journal-title":"Heart"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379722001854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379722001854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:06:25Z","timestamp":1760083585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379722001854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0749379722001854"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2022.03.027","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fixed-Dose Combination (Polypill) for Cardiovascular Disease Prevention: A Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2022.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}